{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:04:59Z","timestamp":1789275899757,"version":"build-2803163510"},"reference-count":48,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003074","name":"Agencia Nacional para la Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"crossref","award":["PICT 2014-1247"],"award-info":[{"award-number":["PICT 2014-1247"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional para la Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"crossref","award":["PICT 2012-1738"],"award-info":[{"award-number":["PICT 2012-1738"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"crossref","award":["D3646\/14"],"award-info":[{"award-number":["D3646\/14"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"crossref","award":["PIP 112 201101 00627"],"award-info":[{"award-number":["PIP 112 201101 00627"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"crossref"}]},{"award":["D3646\/14"],"award-info":[{"award-number":["D3646\/14"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"publisher"}]},{"award":["PIP 112 201101 00627"],"award-info":[{"award-number":["PIP 112 201101 00627"]}],"id":[{"id":"https:\/\/ror.org\/03cqe8w59","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>The\u00a0use of BRAF inhibitors (BRAFi) for the targeted inhibition of the MAPK pathway represents a cornerstone of treatment for BRAFV600E-mutant melanoma. However, the rapid emergence of drug resistance remains a major clinical challenge. Mounting evidence indicates that therapy resistance is driven by both phenotypic plasticity and metabolic reprogramming. This study aimed to investigate the molecular, phenotypic, and metabolic adaptations underlying acquired resistance to the BRAFi GSK2118436 in A375 melanoma cells. BRAFi-resistant cells (A375-R) displayed cross-resistance to additional BRAFi and MEK inhibitors and clear features of epithelial\u2013mesenchymal transition (EMT), including decreased E-cadherin, increased vimentin, and inhibitor-dependent spheroid compaction. Among the multiple metabolic modulators evaluated, inhibitors of mitochondrial respiration\u2014particularly metformin and antimycin A\u2014selectively impaired viability, clonogenicity, sphere formation and 3D growth of resistant cells. Importantly, while simultaneous BRAFi\u2013metformin combination caused mostly antagonist effects, a sequential regimen (BRAFi followed by metformin) elicited additive\/synergistic cytotoxicity in both 2D and 3D models. Collectively, these findings show that BRAFi resistance is driven by coordinated EMT and metabolic rewiring toward OXPHOS dependency and suggest that sequential metabolic targeting is an effective strategy to overcome therapy resistance in melanoma.<\/jats:p>","DOI":"10.3390\/ijms27188088","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:51:37Z","timestamp":1789123897000},"page":"8088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin"],"prefix":"10.3390","volume":"27","author":[{"given":"Mar\u00eda Florencia","family":"Arbe","sequence":"first","affiliation":[{"name":"Unidad de Transferencia Gen\u00e9tica y Laboratorio de Metabolismo Tumoral, \u00c1rea Investigaci\u00f3n, Instituto de Oncolog\u00eda \u00c1ngel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Av. San Mart\u00edn 5481, Buenos Aires C1417DTB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Claudio","family":"Glikin","sequence":"additional","affiliation":[{"name":"Unidad de Transferencia Gen\u00e9tica y Laboratorio de Metabolismo Tumoral, \u00c1rea Investigaci\u00f3n, Instituto de Oncolog\u00eda \u00c1ngel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Av. San Mart\u00edn 5481, Buenos Aires C1417DTB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana Mar\u00eda Elena","family":"Finocchiaro","sequence":"additional","affiliation":[{"name":"Unidad de Transferencia Gen\u00e9tica y Laboratorio de Metabolismo Tumoral, \u00c1rea Investigaci\u00f3n, Instituto de Oncolog\u00eda \u00c1ngel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Av. San Mart\u00edn 5481, Buenos Aires C1417DTB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-9228","authenticated-orcid":false,"given":"Marcela Solange","family":"Villaverde","sequence":"additional","affiliation":[{"name":"Unidad de Transferencia Gen\u00e9tica y Laboratorio de Metabolismo Tumoral, \u00c1rea Investigaci\u00f3n, Instituto de Oncolog\u00eda \u00c1ngel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Av. San Mart\u00edn 5481, Buenos Aires C1417DTB, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-17-0172","article-title":"Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib","volume":"23","author":"Wongchenko","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27819","DOI":"10.1021\/acsomega.3c00332","article-title":"Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022","volume":"8","author":"Singh","year":"2023","journal-title":"ACS Omega"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102795","DOI":"10.1016\/j.ctrv.2024.102795","article-title":"Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma","volume":"129","author":"Loftus","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Aasen, S.N., Parajuli, H., Hoang, T., Feng, Z., Stokke, K., Wang, J., Roy, K., Bjerkvig, R., Knappskog, S., and Thorsen, F. (2019). Effective treatment of metastatic melanoma by combining mapk and pi3k signaling pathway inhibitors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174235"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Luebker, S.A., and Koepsell, S.A. (2019). Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00268"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., and Mangino, G. (2020). Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers, 12.","DOI":"10.3390\/cancers12102801"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1038\/s41598-021-83796-8","article-title":"Screening of metabolic modulators identifies new strategies to target metabolic reprogramming in melanoma","volume":"11","author":"Abildgaard","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1238557","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105691","DOI":"10.1016\/j.rvsc.2025.105691","article-title":"Loss of viability and impairment of the cell cycle by combining metabolic modulators in canine and feline melanoma cells","volume":"191","author":"Pan","year":"2025","journal-title":"Res. Vet. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100842","DOI":"10.1016\/j.tranon.2020.100842","article-title":"Glucose 6-phosphate dehydrogenase inhibition sensitizes melanoma cells to metformin treatment","volume":"13","author":"Arbe","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.rvsc.2017.07.035","article-title":"Inhibition of bioenergetic metabolism by the combination of metformin and 2-deoxyglucose highly decreases viability of feline mammary carcinoma cells","volume":"114","author":"Arbe","year":"2017","journal-title":"Res. Veter.-Sci."},{"key":"ref_13","first-page":"401","article-title":"Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides","volume":"33","author":"Lea","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing metformin: An old drug with new tricks in its binding pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101945","DOI":"10.1016\/j.tranon.2024.101945","article-title":"Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect","volume":"44","author":"Zhu","year":"2024","journal-title":"Transl. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","article-title":"The role and regulation of integrins in cell migration and invasion","volume":"26","author":"Chastney","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jid.2021.10.007","article-title":"Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor\u2013Resistant BRAFV600E\/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model","volume":"142","author":"Jandova","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.18632\/oncotarget.13480","article-title":"Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation","volume":"8","author":"Byeon","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1038\/onc.2012.492","article-title":"Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma","volume":"32","author":"Burridge","year":"2013","journal-title":"Oncogene"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/1535-7163.MCT-14-0701","article-title":"Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts","volume":"14","author":"Paulitschke","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40265-018-0884-8","article-title":"BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers","volume":"78","author":"Sanchez","year":"2018","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cmet.2016.03.006","article-title":"Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy","volume":"23","author":"Dowling","year":"2016","journal-title":"Cell Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating metformin for cancer prevention and treatment: The end of the beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3892\/mmr.2014.2490","article-title":"Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin-resistant ovarian cancer","volume":"10","author":"Xie","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1016\/j.biopha.2018.11.109","article-title":"Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells","volume":"109","author":"Ryabaya","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s42255-026-01530-y","article-title":"Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control","volume":"8","author":"Sebo","year":"2026","journal-title":"Nat. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"10908","DOI":"10.18632\/oncotarget.3434","article-title":"Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: Similarity with calorie restriction","volume":"6","author":"Mert","year":"2015","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1900\/RDS.2013.10.228","article-title":"Metformin and cancer","volume":"10","author":"Vallianou","year":"2013","journal-title":"Rev. Diabet. Stud."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"117276","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/cc.23050","article-title":"Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt","volume":"12","author":"Pattarozzi","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jung, J.W., Park, S.B., Lee, S.J., Seo, M.S., Trosko, J.E., and Kang, K.S. (2011). Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028068"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, X., Li, Z., Liu, L., Zhang, P., Wang, Y., and Ding, G. (2024). Metformin-mediated effects on mesenchymal stem cells and mechanisms: Proliferation, differentiation and aging. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1465697"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-018-0375-1","article-title":"Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1\/anti-CTLA-4) in metastatic malignant melanoma","volume":"6","author":"Afzal","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1633235","DOI":"10.1080\/2162402X.2019.1633235","article-title":"Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy","volume":"8","author":"Verdura","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","article-title":"Cancer drug resistance induced by EMT: Novel therapeutic strategies","volume":"95","author":"Brozovic","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sinha, D., Saha, P., Samanta, A., and Bishayee, A. (2020). Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression. Biomolecules, 10.","DOI":"10.3390\/biom10111561"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"118211","DOI":"10.1016\/j.bcp.2026.118211","article-title":"MAPK-driven remodeling of mitochondrial dynamics in melanoma: Implications for metabolic plasticity and response to targeted therapy","volume":"252","author":"Grabauskas","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1172\/JCI82661","article-title":"Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors","volume":"126","author":"Zhang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Atefi, M., Von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J.A., and Comin-Anduix, B. (2011). Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT\/mTOR Pathway. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0028973"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/acschembio.5c00562","article-title":"A New CombinationTherapy Utilizing Mitochondria-TargetingSmall-Molecule Ligands and Clinical Inhibitors against Melanoma","volume":"21","author":"Chan","year":"2026","journal-title":"ACS Chem. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/cncr.32539","article-title":"Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer","volume":"126","author":"Gulati","year":"2020","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_44","unstructured":"ClinicalTrials.gov (2012). A Phase I\/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients (Standard No. NCT01638676)."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bit.10655","article-title":"Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types","volume":"83","author":"Kelm","year":"2003","journal-title":"Biotechnol. Bioeng."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biopha.2013.01.002","article-title":"Cationic lipid: DNA complexes allow bleomycin uptake by melanoma cells","volume":"67","author":"Rossi","year":"2013","journal-title":"Biomed. Pharmacother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0887-2333(89)90039-8","article-title":"Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs","volume":"3","author":"Saotome","year":"1989","journal-title":"Toxicol. Vitro"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: An interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Fornari","year":"2016","journal-title":"Bioinformatics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:16:55Z","timestamp":1789273015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":48,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188088"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188088","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}